Ivan De Kouchkovsky, MD
Assistant Professor
Medicine
School of Medicine

Publications (11)

Top publication keywords:
RadioimmunotherapyLutetiumReceptors, AndrogenProstatic Neoplasms, Castration-ResistantCarcinoma, NeuroendocrineCarcinoma, Transitional CellPyruvic AcidAdenocarcinomaProstatic NeoplasmsUrinary Bladder NeoplasmsDipeptidesAndrogen Receptor AntagonistsGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingAntigens, Surface

• Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Moradpour M, Moradi Tuchayi A, Yadav S, Jiang F, Burger IA, Pop SG, Surasi DS, Hussein A, Arora I, Aparicio A, de Kouchkovsky I, Flavell RR, Hope TA
• Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized 13C MRI-A Correlative Study with Clinical Outcomes.
  Cancers 2025 Chen HY, de Kouchkovsky I, Bok RA, Ohliger MA, Wang ZJ, Gebrezgiabhier D, Nickles T, Carvajal L, Gordon JW, Larson PEZ, Kurhanewicz J, Aggarwal R, Vigneron DB
• Pre- or post-chemotherapy: effect on PSMA uptake.
  EJNMMI research 2025 Yadav S, Tuchayi AM, Moradpour M, Jiang F, Juarez R, de Kouchkovsky I, Flavell RR, Aggarwal RR, Hope TA
• Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study.
  European journal of nuclear medicine and molecular imaging 2025 Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J
• Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.
  Cancer medicine 2024 Kwon DH, Trihy L, Darvish N, Hearst E, Sumra S, Borno HT, Bose R, Chou J, de Kouchkovsky I, Desai A, Ekstrand B, Friedlander T, Kaur G, Koshkin VS, Nesheiwat S, Sepucha K, Small EJ, Aggarwal RR, …

Show all (6 more) Hide

• Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024 Moradi Tuchayi A, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A, Juarez R, Lawhn-Heath C, Wang Y, de Kouchkovsky I, Hope TA
• Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024 Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA
• Diagnosis and management of neuroendocrine prostate cancer.
  The Prostate 2024 de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer.
  European urology 2021 de Kouchkovsky I, Chen HY, Ohliger MA, Wang ZJ, Bok RA, Gordon JW, Larson PEZ, Frost M, Okamoto K, Cooperberg MR, Kurhanewicz J, Vigneron DB, Aggarwal R